IRWD Ironwood Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why IRWD matters now
Ironwood Pharmaceuticals, Inc. (IRWD) is a US stock in Healthcare. The latest InvestLog snapshot shows $4.47 with -4.28% on the session and $735.8M in market capitalization; recent performance reads 1-month -3.54% and YTD +5.04%.
The latest financial table shown here is Q1 2026, with revenue of $106.5M, net income of $40.8M, and EPS of $0.24. Investors can compare that operating picture with valuation signals such as P/E 24.65 and FCF yield 19.3%.
The latest indexable market news headline is "4 Defensive Stocks to Take Refuge in as Tech Sell-off Continues" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $5.00; recent insider activity includes Moukheibir Catherine filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
24.65
PEG
0.01
P/B
-2.66
P/S
1.61
EV/EBITDA
4.63
DCF Value
$6.57
FCF Yield
19.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.6%
Operating Margin
55.8%
Net Margin
28.3%
ROE
-38.9%
ROA
23.5%
ROIC
30.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $106.5M | $40.8M | $0.24 |
| Q4 2025 | $47.7M | $-2.3M | $-0.01 |
| FY 2025 | $296.2M | $24.0M | $0.15 |
| Q3 2025 | $122.1M | $40.1M | $0.23 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$4.80
Target (Median)
$5.00
Target Range
$3.70 - $5.70
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
0.24
Ironwood Pharmaceuticals, Inc. operates as a healthcare enterprise primarily dedicated to discovering, developing, and commercializing therapeutic solutions for gastrointestinal (GI) conditions. Its flagship commercial product is linaclotide, a guanylate cyclase type-C (GC-C) agonist. This medication is prescribed for adult patients managing irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), sold as LINZESS in the United States and Mexico, and under the CONSTELLA brand throughout Canada and the European Union. Beyond its marketed offerings, Ironwood's development pipeline includes IW-3300, another GC-C agonist targeting various visceral pain conditions, such as interstitial cystitis/bladder pain syndrome and endometriosis. Additionally, the company is advancing CNP-104, an immune nanoparticle being investigated for biliary cholangitis. Ironwood maintains key strategic alliances with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. to support the ongoing development and market introduction of linaclotide. Established in 1998, the Boston, Massachusetts-based firm initially operated as Microbia, Inc. before officially rebranding to Ironwood Pharmaceuticals, Inc. in April 2008.